Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Oral Norovirus Vaccines (GI.1 and GII.4)
NCT03897309Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Mar 2019
- Primary completion
- Jan 2021
- Modality
- Viral Vector Vaccines, Drug Delivery Systems, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VXA-GI.1.NN and VXA-G2.4-NS in norovirus infection (4 arms), sponsored by Vaxart, Inc. Primary endpoints: Rate of Solicited Adverse Events at 1 week, Rate of Unsolicited Adverse Events at 4 weeks and 2 more. Started Mar 2019; status: completed.
02
Drugs
VXA-GI.1.NNVXA-G2.4-NS
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT03897309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897309.